Cipla gets USFDA observations for its Goa plant
New Delhi: Drug firm Cipla said it has received observations from the US health regulator for its Goa plant which are procedural in nature.
The United States Food and Drug Administration (USFDA) had conducted a product-specific pre-approval inspection at company's Goa plant in January 2018, Cipla said in a BSE filing.
"We received certain observations which are procedural in nature. We have already responded to the agency on all the observations," it added.
At this stage, the company does not foresee any impact on the other products being manufactured/filed from the plant, Cipla said.
"Post this inspection, we have received 2 product approvals from the plant," it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd